Your browser doesn't support javascript.
loading
Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B-YOND extension study.
Pasi, K John; Fischer, Kathelijn; Ragni, Margaret; Kulkarni, Roshni; Ozelo, Margareth C; Mahlangu, Johnny; Shapiro, Amy; P'Ng, Stephanie; Chambost, Hervé; Nolan, Beatrice; Bennett, Carolyn; Matsushita, Tadashi; Winding, Bent; Fruebis, Joachim; Yuan, Huixing; Rudin, Dan; Oldenburg, Johannes.
Affiliation
  • Pasi KJ; Royal London Haemophilia Centre, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
  • Fischer K; Van Creveldkliniek, University Medical Center, Utrecht, Netherlands.
  • Ragni M; Hemophilia Center of Western Pennsylvania, University of Pittsburgh, Pittsburgh, PA, USA.
  • Kulkarni R; Michigan State University, East Lansing, MI, USA.
  • Ozelo MC; Hemocentro UNICAMP, University of Campinas, Campinas, Brazil.
  • Mahlangu J; Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand, and Charlotte Maxeke Johannesburg Academic Hospital and National Health Laboratory Service, Johannesburg, South Africa.
  • Shapiro A; Indiana Hemophilia & Thrombosis Center, Inc., Indianapolis, IN, USA.
  • P'Ng S; The Haemophilia and Haemostasis Centre, Fiona Stanley Hospital, Murdoch, WA, Australia.
  • Chambost H; Children's Hospital La Timone, and Aix Marseille University, INSERM, INRA, C2VN, Marseille, France.
  • Nolan B; Children's Health Ireland at Crumlin, Dublin, Ireland.
  • Bennett C; Emory University School of Medicine, Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta, Atlanta, GA, USA.
  • Matsushita T; Nagoya University Hospital, Nagoya, Japan.
  • Winding B; Sobi, Stockholm, Sweden.
  • Fruebis J; Bioverativ, a Sanofi company, Waltham, MA, USA.
  • Yuan H; Sanofi, Waltham, MA, USA.
  • Rudin D; Bioverativ, a Sanofi company, Waltham, MA, USA.
  • Oldenburg J; Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany.
Haemophilia ; 26(6): e262-e271, 2020 Nov.
Article in En | MEDLINE | ID: mdl-32497409
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Recombinant Fusion Proteins / Factor IX / Immunoglobulin Fc Fragments / Hemophilia B Limits: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male / Middle aged Language: En Journal: Haemophilia Journal subject: HEMATOLOGIA Year: 2020 Document type: Article Affiliation country: Reino Unido Country of publication: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Recombinant Fusion Proteins / Factor IX / Immunoglobulin Fc Fragments / Hemophilia B Limits: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male / Middle aged Language: En Journal: Haemophilia Journal subject: HEMATOLOGIA Year: 2020 Document type: Article Affiliation country: Reino Unido Country of publication: Reino Unido